Dependence of peripheral T‐cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dependence of peripheral T‐cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach
Authors
Keywords
-
Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-25
DOI
10.1002/hon.3233
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas
- (2022) Mathew G. Angelos et al. Journal of Personalized Medicine
- A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine–related JAK-STAT signal
- (2022) Chengjuan Chen et al. Science Advances
- NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
- (2021) Elissa Andraos et al. Cancers
- JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL)
- (2021) Chella Krishna Vadivel et al. Cancers
- Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis
- (2021) Kang Le et al. Blood Advances
- Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma
- (2021) Elif Karaca Atabay et al. BLOOD
- A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
- (2021) Alison J. Moskowitz et al. BLOOD
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
- (2021) S. Horwitz et al. ANNALS OF ONCOLOGY
- Phase two study of crizotinib in patients with anaplastic lymphoma kinase ( ALK ) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
- (2020) Elisa Bossi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Protein tyrosine phosphatases in multiple myeloma
- (2020) Pegah Abdollahi et al. CANCER LETTERS
- International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma
- (2017) Matthew J. Maurer et al. JOURNAL OF CLINICAL ONCOLOGY
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
- (2017) Atli Thorarensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma
- (2017) Jun Soo Ham et al. Oncotarget
- Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
- (2016) Jean-Baptiste Telliez et al. ACS Chemical Biology
- Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma
- (2015) Ramona Crescenzo et al. CANCER CELL
- Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma
- (2015) Christos Demosthenous et al. Oncotarget
- A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling
- (2013) Guangzhen Hu et al. PLoS One
- JAK/STAT signaling in hematological malignancies
- (2012) W Vainchenker et al. ONCOGENE
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
- (2008) JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search